Cornelia Mauch
Assistant professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (3)
PFS in ( A ) part I/run-in and ( B ) part II. A, Kaplan–Meier analysis of PFS with encorafenib plus binimetinib in naïve and pretreated patients in the FAS population. B, Kaplan–Meier analysis of PFS in the encorafenib plus binimetinib and ribociclib, encorafenib plus binimetinib and capmatinib, and encorafenib plus binimetinib and buparlisib arms.
Year:
2025
Purpose: LOGIC 2 (NCT02159066), a multicenter, open-label, two-part, phase II study, assessed encorafenib plus binimetinib combined with a third targeted agent after tumor progression on encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAF V600 -mutant melanoma. Patients and Methods: Adults with locally advanced, unresectable or metastatic BRAF V600 -mutant melanoma who were BRAF inhibitor/MEK inhibitor (BRAFi/MEKi) treatment–naïve or pretreated received encorafenib plus binimetinib (part I/run-in). Based on the genomic testing at disease progression following encorafenib plus binimetinib, patients were assigned to one of four treatment arms to receive encorafenib plus binimetinib with an appropriate molecularly targeted agent (ribociclib, infigratinib, capmatinib, or buparlisib; part II). The primary endpoint was best overall response; safety, biomarkers, pharmacokinetics, and other efficacy endpoints were also assessed. Results: In part I/run-in, 75 BRAFi/MEKi-naïve patients and 83 BRAFi/MEKi-pretreated patients were treated; in part II, 58 patients were treated (ribociclib, n = 38; infigratinib, n = 1; capmatinib, n = 13; buparlisib, n = 6). The overall confirmed response rate was 73.3% [95% confidence interval (CI), 61.9–82.9] in BRAFi/MEKi-naïve patients, 25.3% (95% CI, 16.4–36.0) in pretreated patients, 2.6% (95% CI, 0.1–13.8) in the ribociclib arm, and 0% in the other three arms. Adverse events were manageable and consistent with the known safety profile of each drug. Conclusions: LOGIC 2 supports the use of encorafenib plus binimetinib for treatment-naïve and previously treated, locally advanced, unresectable or metastatic BRAF V600 -mutant melanoma. However, adding a third targeted agent following disease progression did not show meaningful efficacy; further research is needed to identify other therapeutic targets to circumvent resistance.
Year:
2025
LOGIC 2 study design. A multicenter, open-label, two-part, phase II study to assess the efficacy and safety of encorafenib plus binimetinib (part I) followed by encorafenib plus binimetinib combined with a third targeted agent after tumor progression (part II) in patients with locally advanced, unresectable or metastatic BRAF V600 -mutant melanoma. a Single agents include vemurafenib, dabrafenib, encorafenib, trametinib, and binimetinib; combinations include dabrafenib/trametinib and encorafenib/binimetinib. b Patients who experienced PD on a prior BRAFi/MEKi regimen continued encorafenib/binimetinib if a PR was observed followed by a new biopsy at progression. Patients who did not progress on their prior regimen could continue the encorafenib/binimetinib combination until evidence of PD, at which point a tumor biopsy would be taken and analyzed to guide assignment to a triplet combination arm in part II.
Year:
2025
Collaborators (10)
Jessica C. Hassel
Heidelberg University
Reinhard Dummer
University Hospital of Zurich
Bartosz Chmielowski
Ronald Reagan UCLA Medical Center
Marcus Butler
University Health Network
Wilson H Miller Jr
McGill University
Michael A. Postow
Weill Cornell Medical College
Lucie Heinzerling
University Hospital
Shahneen Sandhu
-
Mark Middleton
University of Oxford
Paolo Antonio Ascierto
Full Professor
Università degli Studi di Napoli Federico II
Make your next move.
Prepare your application
Review drafts before you send them.